Clarity Pharmaceuticals
Copper theranostics company: Cu-64 SAR-bisPSMA for PET (phase 3 AMPLIFY/CLARIFY) and Cu-67 SAR-bisPSMA for therapy.
Co-PSMA head-to-head data (EAU 2026) showed Cu-64 SAR-bisPSMA more than doubled lesion and patient detection versus Ga-68 PSMA-11; FDA Fast Track in biochemical recurrence; commercial manufacturing agreement with Nucleus RadioPharma (April 2026). SECuRE therapy trial: 7 of 19 patients at 8 GBq 67Cu reached complete response or undetectable disease (July 2026).
Pages like this
not linked directly; found by shared links- PersonJeremie Calais
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonThomas A. Hope
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonRahul Aggarwal
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonPeter Bartenstein
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonJohannes Czernin
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- PairingPSMA PET → PSMA radioligand therapy
Shares Theranostics, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- ProductFlotufolastat F-18
Shares PSMA, PSMA PET, Prostate cancer.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Theranostics, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.